Compare TKNO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | TTRX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.1M | 116.0M |
| IPO Year | N/A | N/A |
| Metric | TKNO | TTRX |
|---|---|---|
| Price | $2.01 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 371.9K | 31.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.64 | N/A |
| Revenue Next Year | $9.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.91 | $2.57 |
| 52 Week High | $8.65 | $26.50 |
| Indicator | TKNO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 16.20 | 31.93 |
| Support Level | $1.96 | $3.55 |
| Resistance Level | $2.26 | $3.80 |
| Average True Range (ATR) | 0.28 | 0.27 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 6.59 | 2.35 |
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.